PP_1170x120_10-25-21

Gilotrif

Boehringer Ingelheim’s Gilotrif approved for new indication

Boehringer Ingelheim’s Gilotrif approved for new indication

RIDGEFIELD, Conn. — After being granted a priority review from the Food and Drug Administration this past fall, Boehringer Ingelheim Pharmaceuticals Inc. has received approval of its supplemental New Drug Application (sNDA) for Gilotrif (afatinib), a lung cancer medication. Boehringer Ingelheim said Gilotrif is indicated for the first-line treatment of patients with metastatic non-small cell lung